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There  is  great  variability  in  drug  response,  whether 
measured  in  terms  of  efficacy  or  toxicity.  Part  of  this 
variability is due to direct biological factors that influence 
the bioavailability and effects of a drug on its target, and 
part is due to indirect factors (psychological or social) 
related to patient adherence, access to care, and physician 
prescribing  practices.  With  regard  to  direct  biological 
factors,  the  efficacy  and  toxicity  of  a  medication  are 
determined by the balance between its pharmacokinetics 
(absorption, distribution, metabolism and elimination of 
the drug) and its pharmacodynamics (the physiological 
effect of the active drug at the site of biological action). 
Inherited genetic variation contributes to this variability, 
as multiple genes encode proteins directly involved in the 
pharmacokinetics  and  pharmacodynamics  of  drugs. 
Pharma  cogenetic research aims to investigate the asso­
ciation  of  inherited  genetic  variants  with  response  to 
drug therapy, including drug efficacy or adverse effects. 
Pharmacogenomics  brings  this  search  for  genetic 
determinants of drug response to the scope of the entire 
genome.
As systematic queries of the human genome become 
more feasible on a large scale, a number of advantages for 
pharmacogenetic investigation become evident (Table 1). 
First,  by  casting  an  agnostic  net  in  search  of  genetic 
determinants of drug response, pharmacogenomics can 
uncover  novel  molecular  targets  for  commonly  used 
drugs, which serve to illuminate previously unsuspected 
mechanisms of action. Second, insofar as such mecha­
nisms point to specific cellular pathways, this approach 
has the potential to illuminate the patho  physiology of the 
disease affected by the drug. Third, in so doing, a more 
nuanced understanding of the processes that give rise to 
a  pathological  state  can  help  refine  the  nosology  of 
disease,  clarifying  its  heterogeneity  and  establishing 
particular  subtypes.  Fourth,  pharmaco  genetic  experi­
ments  can  help  demonstrate  that  one  of  several  genes 
within a genomic region previously associated with the 
trait does indeed cause the disease process: by perturbing 
a  live  human  with  a  drug  that  targets  that  gene  and 
assessing their response to the perturbation, the investi­
gator may be able to ‘close the loop’ and demonstrate that 
the associated gene is indeed involved in producing the 
phenotype of interest. And fifth, cataloguing the genetic 
determinants  of  drug  response  can  guide  the 
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efficacy. Examples abound: such personalized therapy is 
now  the  standard  of  care  for  azathioprine  [1,2]  and 
abacavir [3] to avoid drug­related complications, and for 
certain forms of cancer to achieve better outcomes [4­7]. 
Safety  and  efficacy  concerns  both  suggest  that  similar 
precautions may need to be taken for other drugs with a 
narrow therapeutic index (where the therapeutic dose is 
close to the dose that produces adverse effects), such as 
warfarin [8­10] and clopidogrel [11­14].
As  far  as  diabetes  is  concerned,  pharmacogenetic 
approaches have already had a substantial impact on rare, 
monogenic forms of diabetes. Maturity onset diabetes of 
the young (MODY) is characterized by onset at young 
age, autosomal dominant transmission and a non­ketotic 
presentation  in  typically,  but  not  always,  non­obese 
people. It is caused by mutations in the genes that encode 
glucokinase and several transcription factors relevant to 
pancreatic β­cell development [15]. Patients with trans­
crip  tion  factor  MODY  respond  better  to  sulfonylureas 
than  to  metformin  [16],  illustrating  the  pathophysio­
logical mechanisms centered in the β cell (where insulin 
secretagogues such as sulfonylureas act) for this form of 
the disease. Similarly, neonatal diabetes, diagnosed by the 
onset of hyperglycemia within the first 6 months of life, is 
caused by activating mutations in the islet ATP­sensitive 
potassium  channel  Kir6.2  (encoded  by  KCNJ11)  or  its 
asso  ciated  sulfonylurea  receptor  SUR1  (encoded  by 
ABCC8), which interfere with the ability of the β cell to 
respond to a glucose load. These patients can be effec  t­
ively treated by high­dose sulfonylureas [17­20], allowing 
children  mistakenly  diagnosed  with  type  1  diabetes 
(based on the early onset of disease and undetectable C 
peptide)  to  be  safely  transitioned  from  multiple  daily 
insulin  injections  to  an  oral  agent  once  the  correct 
genetic diagnosis is made.
Whether  pharmacogenetics  will  have  an  analogous 
impact on common type 2 diabetes (T2D), the subject of 
this review, remains to be seen. T2D is one of the leading 
causes of cardiovascular disease, microvascular compli­
cations and death in the USA and worldwide. Its inci­
dence has been rising steadily over the past few decades, 
and  is  predicted  to  reach  epidemic  proportions  in 
developing nations. Despite this obvious environmental 
contribution to the disease, it is now recognized that T2D 
pathogenesis  is  driven  by  multiple  genetic  factors 
interacting with a metabolically deleterious environment 
[21]. In recent years, well­powered candidate gene studies 
and  genome­wide  association  studies  (GWASs)  have 
uncovered over 40 genomic loci that are associated with 
T2D  at  genome­wide  levels  of  statistical  significance 
(P < 5 × 10­8, determined empirically to account for the 
number  of  independent  hypotheses  among  common 
variants in the European genome [22]). However, these 
associations simply point to areas of the genome that are 
overrepresented in cases of T2D when compared with 
non­diabetic controls; in most cases, the exact identity of 
the culprit gene and the causal variant remain unknown 
[23].
Many  oral  anti­diabetes  medications  have  been 
developed  and  used  in  clinical  practice  for  years,  but 
some of their biological mechanisms are not completely 
understood.  Figure  1  illustrates  the  tissues  targeted  by 
current anti­diabetes medications. Pharmacogenetics has 
proven  invaluable  in  guiding  therapeutic  choices  in 
MODY  and  neonatal  diabetes,  and  its  extension  to 
common T2D is now beginning to take place. In the past 
10  years,  three  major  approaches  for  pharmacogenetic 
discovery  have  evolved  in  parallel  with  technological 
development: candidate gene studies opened the way to 
large­scale genotyping studies, which were followed by 
GWASs. In the early stages of genetic investigation only 
common  variation  in  candidate  genes  could  be 
realistically  examined,  because  of  limited  efficiency  in 
genotyping  and  imperfect  knowledge  of  the  human 
genome  and  its  patterns  of  variation.  As  large­scale 
genotyping based on a comprehensive haplotype map of 
the human genome became available for deployment in 
larger samples, GWASs became a powerful research tool 
enabling  the  transition  from  pharmacogenetics  to 
pharma  co  genomics  in  T2D.  Here,  we  review  the  most 
current  pharmacogenetic  evidence  in  T2D  based  on 
these different approaches, confining our remarks to the 
studies and drug classes (sulfonylureas, metformin, and 
thiazolidinediones) that have gathered the most conclu­
sive evidence in this regard. For a comprehensive list of 
Table 1. Potential contribution of pharmacogenetic approaches
Advantage	 Explanation
Discovery of new drug targets  Agnostic genome-wide approaches are not contingent on prior biological knowledge
Mechanistic insight  Discoveries of new pathways may illuminate the pathophysiology of the disease process that is targeted by a given drug
Nosology of disease  Understanding of molecular pathways can help explain disease heterogeneity and classify its various subtypes 
Fine-mapping  Detecting a drug-gene interaction can pinpoint the specific gene under a genomic association signal that is likely to  
  harbor the causal genetic variant
Personalized medicine  Genetic determinants of drug response may result in individualized approaches to therapy based on the likelihood of  
  effectiveness and tolerance
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systematic review [24].
Candidate genes
These  studies  focus  on  a  few  plausible  candidate  genes 
involved in drug pharmacokinetics/pharmacodynamics, or 
those associated with T2D as a disease phenotype. Here we 
focus on sulfonylureas, metformin and thia  zo  lidinediones.
Sulfonylureas
Cytochrome  P450  2C9  (CYP2C9)  is  the  rate­limiting 
enzyme in the metabolism of many sulfonylureas, such as 
glipizide,  glimepiride  and  tolbutamide.  For  glyburide, 
although  CYP3A4  contributes  more  than  50%  of  the 
formation of total metabolites, CYP2C9 also contributes 
30% of the formation of metabolites. The wild­type allele 
of the CYP2C9 gene is CYP2C9*1; the two allelic variants 
CYP2C9*2 (rs1799853) and CYP2C9*3 (rs1057910) encode 
the loss­of­function missense amino acid poly  morphisms 
*2 (Arg144Cys) and *3 (Ile359Leu), respectively. Pharmaco­
kinetic analysis of glyburide was performed in 21 healthy 
volunteers with all 6 combinations of the CYP2C9 alleles 
*1, *2 and *3. Homozygous carriers of the CYP2C9*3/*3 
genotypes  had  reduced  clearance  of  glyburide  and 
increased insulin secretion 12 hours after glyburide inges­
tion [25], a finding that was confirmed by others [26,27]. In 
Japanese T2D patients, those with CYP2C9*1/*3 genotypes 
had  significantly  elevated  plasma  concentrations  of 
glimepiride  and  a  greater  reduction  in  glycated  hemo­
globin (HbA1C) than those with CYP2C9*1/*1 [28]. Much 
larger studies have been made possible by the compilation 
of prescription information and clinical outcomes from 
electronic medical records, focused on patients with T2D 
who have also consented to donate a DNA sample. Using 
this retrospective approach, the GoDARTS investigators 
in  Tayside,  Scotland,  examined  1,073  incident  users  of 
sulfonylureas:  patients  with  two  copies  of  the  *2  or  *3 
alleles were 3.4 times more likely to achieve treatment 
targets (HbA1C levels under 7%) than patients with two 
wild­type CYP2C9 alleles [29].
Sulfonylureas bind to the pancreatic β­cell sulfonylurea 
receptor SUR1 coupled to the ATP­dependent potassium 
Figure	1.	Proposed	tissue	targets	of	the	major	classes	of	anti-diabetes	medications. For details, see Table 2. Although the primary 
tissue targets are shown, many of these drugs have multi-organ effects. The dotted line denotes putative mechanisms that remain to be fully 
demonstrated in humans. DPP-IV, dipeptidyl peptidase-IV; GI, gastrointestinal tract; GLP-1, glucagon-like peptide-1; TZDs, thiazolidinediones.
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Page 3 of 9channel  Kir6.2,  causing  channel  closure  and  triggering 
insulin  secretion  in  a  glucose­independent  manner.  As 
mentioned above, activating mutations in their respective 
genes,  ABCC8  and  KCNJ11  [17,20],  cause  neonatal 
diabetes  mellitus.  The  K  (Lys)  allele  at  the  common 
Glu23Lys polymorphism in KCNJ11 has been shown to 
be associated with increased risk of T2D by several large 
studies  [30­33].  Interestingly,  KCNJ11  and  ABCC8  lie 
next to each other on chromosome 11, and are separated 
by  only  5  kb:  a  large  region  of  linkage  disequilibrium 
imposes strong correlation among several variants across 
both  genes  [33].  Another  missense  polymorphism, 
Ala1369Ser in ABCC8, is highly correlated with KCNJ11 
Glu23Lys  in  all  populations  examined,  such  that  any 
association  signal  at  KCNJ11  Glu23Lys  is  genetically 
indistinguishable  from  ABCC8  Ala1369Ser  [33,34]:  in 
other words, carriers of the risk K allele at Glu23Lys almost 
always carry the A (Ala) allele at Ala1369Ser. Functional 
studies have tried to establish which of the two missense 
variants is causal: in recent elegant work, Hamming and 
colleagues  [35]  have  demonstrated  that  the  A  allele  at 
Ala1369Ser is responsible for the increased responsiveness 
to gliclazide shown by mutated channels in vitro.
In one early report, diabetic carriers of the risk K allele 
at KCNJ11 Glu23Lys were found to have a higher risk for 
secondary  sulfonylurea  failure,  which  was  defined  as 
fasting  plasma  glucose  greater  than  300  mg/dl  despite 
sulfonylurea  treatment  followed  by  sulfonylurea­met­
formin combined therapy [36]. This finding, which could 
also  be  interpreted  as  genetically  driven  diabetes 
progression,  received  some  support  from  a  smaller 
independent  study  [37].  However,  in  a  much  larger 
prospective  study  of  1,268  Chinese  patients  with  T2D, 
carriers of the risk A allele at ABCC8 Ala1369Ser showed 
improved short­term response to gliclazide, in a manner 
consistent with the functional work described above and 
with the results obtained in neonatal diabetes [38]. These 
two  disparate  observations  might  be  reconciled  if  the 
increased initial responsiveness to sulfonylureas shown 
by carriers of the risk allele evolves into β­cell exhaustion 
and  earlier  sulfonylurea  failure,  but  such  hypotheses 
require longer term follow­up.
Table 2. Targets, clinical responses and candidate genes involved in drug response of anti-diabetes medications
	 	 	 	 Candidate	genes	
	 Mechanism	 	 Potential	 putatively	affecting	
Drugs	 of	action	 Main	effect(s)	 adverse	events	 response
Sulfonylureas ATP-dependent K channel 
inhibition
↑ Insulin secretion
↓ Glucagon secretion
Hypoglycemia, allergic reaction 
to sulfa drugs 
CYP2C9, ABCC8, KCNJ11, 
TCF7L2
Metformin AMP-dependent kinase 
(AMPK) activation
↑ Insulin sensitivity
↓ Hepatic gluconeogenesis
Lactic acidosis SLC22A1, SLC47A1, ATM
Thiazolidinediones Enhance PPARγ binding to 
its DNA response element
↑ Glucose uptake by skeletal muscle
↑ Lipolysis
↓ Hepatic glucose output
Fluid overload, congestive heart 
failure, fractures, hepatotoxicity, 
bladder cancer
ADIPOQ, CYP2C8
Insulin  Insulin/IGF-1 receptor 
pathway
↑ Tissue glucose uptake Hypoglycemia ??
Meglitinides  ATP-dependent K channel 
inhibition
↑ Insulin secretion
↓ Glucagon secretion
Hypoglycemia ??
α-Glucosidase 
inhibitors
Inhibit pancreatic α-amylase 
and intestinal α-glucosidase
Glucose absorption by GI tract Hypoglycemia ??
Amylin minetics Amylin receptor pathway ↓ Gastric emptying rate
↑ Insulin secretion
↓ Glucagon secretion
Hypoglycemia ??
GLP-1 mimetics GLP-1 receptor pathway ↑ Glucose-dependent insulin secretion
↓ Gastric emptying rate
↑ Satiety
↓ Glucagon secretion
Nausea, vomiting, hypoglycemia, 
acute pancreatitis, angioedema, 
anaphylaxis
??
DPP-IV inhibitors GLP-1 receptor pathway ↑ Glucose-dependent insulin secretion ??
For details, see authoritative reviews [71-74] and recent clinical guidelines [75-77]. DPP-IV, dipeptidyl peptidase-IV; GI, gastrointestinal tract; GLP-1, glucagon-like 
peptide-1; IGF, insulin-like growth factor.
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(TCF7L2)  harbor  the  strongest  association  with  T2D 
reported  to  date,  which  is  present  in  nearly  all  ethnic 
groups [39,40]. Fine­mapping and functional work have 
shown that the intronic rs7903146 is the likely cause of 
the association signal [41,42]. Carriers of the risk allele at 
this locus show diminished β­cell function [43,44]. There­
fore, it is of great interest to verify whether sulfonylurea 
therapy  works  differently  depending  on  genotype  at 
TCF7L2. This hypothesis was also tested in GoDARTS: 
individuals  with  the  T2D­associated  homozygous  TT 
geno  type  were  less  likely  to  respond  to  sulfonylurea 
therapy and reach the treatment target of HbA1C under 
7% [45]. No such effect was seen for metformin, where 
genotype at TCF7L2 did not make a difference. Consis­
tent results have been published recently in two indepen­
dent  central  European  cohorts  [46,47].  The  contrast 
between  TCF7L2  (where  the  T2D  risk  genotype  is 
associated with a weaker response to sulfonylureas) and 
KCNJ11/ABCC8  (in  which  the  genotypes  that  increase 
risk  of  T2D  are  associated  with  a  stronger  response) 
illustrates  that  disease  association  does  not  necessarily 
predict  the  direction  of  pharmacogenetic  impact: 
whether it is beneficial or harmful may depend on the 
points along the relevant physiological pathway at which 
the gene and the drug exert their respective effects.
Metformin
Metformin  is  a  safe  and  effective  first­line  biguanide 
agent  in  T2D  therapy  [48­51].  It  improves  insulin 
sensitivity, reduces hepatic gluconeogenesis and causes 
modest weight loss [52]. Although it has been shown to 
activate the cellular fuel sensor AMP­dependent kinase 
(AMPK)  [53,54],  other  mechanisms  independent  of 
AMPK activity have also been proposed [55]. Its pharma­
co  kinetics  involves  two  key  processes  in  humans:  the 
organic cation transporters OCT1 and OCT2 (encoded 
by  SLC22A1  and  SLC22A2,  respectively)  mediate 
metformin  transmembrane  transport  into  hepatocytes 
and renal tubular cells, respectively; the multidrug and 
toxin extrusion protein MATE1 (encoded by SLC47A1) 
facilitates excretion of unchanged metformin into urine 
and  bile.  Nonsynonymous  polymorphisms  in  SLC22A1 
have been found to be associated with different plasma 
concentration of metformin in small European and Asian 
cohorts [56,57]; the key results in Europeans were not 
replicated  in  the  retrospective  but  much  larger 
GoDARTS  cohort  [58].  A  smaller  retrospective  study 
based  on  clinical  records  has  also  been  established  in 
Rotterdam: Becker et al. [59] found that the non­coding 
genetic variant rs622342 in SLC22A1 is associated with 
changes  in  HbA1C  levels  after  metformin  treatment,  a 
finding  that  awaits  replication.  Also  in  Rotterdam,  the 
rs2289669  non­coding  polymorphism  in  SLC47A1  was 
associated  with  metformin  response:  a  0.30%  HbA1C 
reduction  was  reported  per  minor  A  allele  compared 
with the G allele [60]. This result has been reproduced in 
the Diabetes Prevention Program (DPP; see below) [61].
Thiazolidinediones
Thiazolidinediones  increase  glucose  uptake  by  skeletal 
muscle, enhance lipolysis and suppress hepatic glucose 
output  by  enhancing  the  binding  of  the  peroxisome 
proliferator­activated  receptor  γ  (PPARγ)  to  its  target 
DNA  response  element.  The  missense  mutation  in  its 
gene PPARG that causes a proline to alanine change at 
codon 12 of the protein has been consistently associated 
with  protection  from  T2D  [62].  However,  this  poly­
morphism does not predict changes in fasting glucose, 
HbA1C levels or insulin sensitivity after treatment with a 
variety  of  thiazolidinedione  agents  [63­65].  Putative 
associations of other variants in this gene with response 
to troglitazone [66] have not been replicated [65].
Other genes have been investigated for association with 
thiazolidinedione response. Kang et al. [67] found that 
two  variants  in  the  adiponectin  gene  (ADIPOQ)  were 
associated  with  changes  in  fasting  glucose  and  HbA1C 
levels after 12 weeks of rosiglitazone treatment. Genetic 
variation  in  CYP2C8  was  found  to  be  associated  with 
altered clearance rate of rosiglitazone [68]. These results 
require confirmation.
Large-scale genotyping studies
As genotyping platforms accommodated higher through­
put, investigators could focus on hundreds or thousands 
of  variants  simultaneously,  either  selected  from  the 
literature or attempting to capture common variation in 
candidate  genes  comprehensively.  Following  this 
approach, the DPP investigators studied the association 
of  1,590  single  nucleotide  polymorphisms  (SNPs)  with 
metformin response, defined as its ability to prevent or 
delay  the  onset  of  diabetes,  in  2,994  DPP  participants 
who  were  at  high  risk  of  T2D  [61].  These  SNPs  in  40 
genes were selected because they are either associated 
with  T2D  according  to  early  GWASs,  encode  drug­
metabolizing/transporting enzymes, or were involved in 
relevant  physiological  processes.  A  variant  in  strong 
linkage  disequilibrium  with  the  polymorphism  in  the 
metformin  transporter  gene  SLC47A1  reported  by  the 
Rotterdam  group  [60]  (see  above)  was  associated  with 
metformin  response.  A  number  of  other  loci  showed 
suggestive associations, but none of them reached statis­
tical  significance  after  correction  for  the  number  of 
hypotheses tested.
The  TRoglitazone  In  the  Prevention  Of  Diabetes 
(TRIPOD)  study  was  a  single­center,  randomized,  and 
double­blinded  clinical  trial  aiming  to  investigate  the 
effect  of  troglitazone  on  T2D  incidence  in  Hispanic 
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who  received  troglitazone,  63  had  improvement  in 
insulin sensitivity and 30 did not. The TRIPOD investi­
gators sequenced 40 kb of PPARG and 133 SNPs were 
identified in the PPARG region. Eight of 133 SNPs were 
found to be nominally associated with improvement in 
insulin sensitivity, but not with change in fasting glucose 
[66]. However, these associations were not corrected for 
multiple testing nor substantiated in the DPP [65].
Genome-wide association studies
The  first  GWAS  for  glycemic  response  to  any  anti­
diabetic drug was conducted by a collaboration formed 
by  GoDARTS,  the  UK  Prospective  Diabetes  Study 
(UKPDS) clinical trial [50] and the Wellcome Trust Case­
Control Consortium [69] and focused on metformin. The 
discovery GWAS cohort included 1,024 individuals from 
Tayside,  Scotland;  follow­up  cohorts  included  an  addi­
tional  1,783  GoDARTS  participants  and  1,113  UKPDS 
participants.  The  first  cohort  underwent  genome­wide 
genotyping,  and  14  SNPs  showing  a  suggestive  asso­
ciation  with  metformin  response  as  a  categorical  trait 
(defined as achieving HbA1C ≤ 7%) at P < 10­6 were taken 
forward into the other two cohorts. These SNPs concen­
trated around the Ataxia­telangiectasia mutated (ATM) 
gene  in  chromosome  11q22,  and  showed  consistent 
associations with metformin response as a quantitative 
trait. During the replication attempt, the minor A allele 
at  rs11212617  was  again  associated  with  increased 
metformin  response  in  both  cohorts,  and  achieved 
conventional  genome­wide  statistical  significance  on 
meta­analysis (P = 2.9 × 10­9). In functional experiments, 
the  authors  further  showed  that  the  selective  ATM 
inhibitor  KU­55933  inhibited  metformin  activation  of 
AMPK in rat hepatoma cells as well as phosphorylation 
of  AMPK  and  a  downstream  target,  implicating  ATM 
itself as the gene responsible for the association signal 
[69]. Minor limitations of this landmark study include the 
relatively small sample size for a GWAS, the somewhat 
arbitrary  definition  of  clinical  response,  and  the 
unexplained connection between the SNP itself and the 
effects seen in the in vitro assays.
Translating pharmacogenetic information into 
clinical practice
Promise
Pharmacogenetic research in T2D has already advanced 
our  understanding  of  the  pathophysiology  of  hyper­
glycemia, by highlighting the β cell as a nodal point in its 
pathogenesis.  Furthermore,  pharmacogenetic  investiga­
tion  has  already  begun  to  deliver  on  the  promise  of 
individualized  therapy  for  some  monogenic  forms  of 
diabetes. Table 2 summarizes our current understanding 
of  the  drug  targets,  clinical  responses,  and  candidate 
genes involved in the human response to anti­diabetes 
medications.  In  T2D,  it  seems  that  slower  metabolism 
due to the CYP2C9*2 and *3 polymorphisms can result in 
improved  glycemic  control  but  more  severe  hypo  gly­
cemia, information that may be useful to the practitioner. 
In  addition,  although  carriers  of  the  risk  genotype  at 
KCNJ11/ABCC8 respond better to gliclazide, carriers of 
the  risk  genotype  at  TCF7L2  are  worse  candidates  for 
sulfonylurea  therapy.  Finally,  extension  of  the  GWAS 
approach  to  larger,  better  powered  meta­analyses  and 
other drug classes may reveal new mechanisms of action.
Barriers
However, several obstacles stand in the way of widespread 
pharmacogenetic  applications.  First,  T2D  is  a  complex 
disease (or group of diseases), caused by the higher order 
interaction of many common (and possibly rare) variants 
among  themselves  and  with  the  environment.  Thus, 
deciding  which  of  these  genetic  factors  are  clinically 
actionable requires renewed discovery and experimental 
testing in appropriately designed and rigorously analyzed 
pharmacogenetic protocols. These trials should not only 
demonstrate genetic effects, but also show that acting on 
genetic information before prescribing specific therapies 
leads  to  better  outcomes  and  is  cost­effective.  Second, 
drug­drug and gene­environment (lifestyle) interactions 
may  override  the  genetic  determinants  of  medication 
response: for example, in the DPP an intensive lifestyle 
intervention benefits all participants regardless of genetic 
burden [70], and it is possible that higher pharmacological 
doses  may  simply  overcome  the  modest  resistance 
induced  by  genetics.  Third,  for  pre­prescription  geno­
typing  to  be  practical,  all  clinically  actionable  variants 
(not  just  for  T2D  or  anti­diabetic  drugs,  but  for  all 
common phenotypes and medications) should be placed 
on a single array that can be processed efficiently and 
cheaply  in  Clinical  Laboratory  Improvement  Amend­
ments (CLIA)­certified laboratories, and only once in the 
lifetime of each patient. This will require the coordination 
of  investigators  involved  in  multiple  areas  of  human 
health,  constant  updating,  and  the  participation  of 
manufacturing companies to produce such arrays on a 
large scale.
Conclusions
In  summary,  it  appears  that  genetic  variation  in  the 
cytochrome  P450  system  affects  response  to  sulfonyl­
ureas.  Among  T2D­associated  loci,  carriers  of  the  risk 
allele at TCF7L2 show a poorer response to sulfonylureas, 
whereas  carriers  of  the  risk  alleles  at  the  sulfonylurea 
receptor complex encoded by ABCC8 and KCNJ11 seem 
to  have  a  stronger  response  to  gliclazide,  a  finding 
supported by in vitro data. Variation in the gene encoding 
the metformin transporter, SLC47A1, may influence the 
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GWAS  for  metformin  response  merit  independent 
confirmation.
Although significant progress has been made in T2D 
pharmacogenetics, the field is still in its infancy. Much 
work  is  needed  in  performing  comprehensive  assess­
ments  of  genetic  variation  across  well  phenotyped, 
sufficiently large sample collections, which can typically 
be  attained  only  in  the  setting  of  international 
collaborations. For future pharmacogenetic research, the 
pre­competitive  participation  of  pharmaceutical  com­
panies,  which  could  contribute  DNA  samples  and 
outcomes  garnered  during  multiple  clinical  trials  that 
compare  proprietary  compounds  with  generic  drugs, 
may be crucial. Phenotypes should be harmonized and 
the definition of drug response should have both clinical 
value  and  biological  relevance.  Once  bona  fide  genetic 
signals are identified, they should be followed up with 
targeted pharmacogenetic studies that evaluate whether 
these associations can be modulated by using different 
dosing regimens or whether the a priori use of genetic 
information improves patient outcomes.
In  conclusion,  we  stand  at  a  threshold  where  the 
question  of  whether  genetic  information  will  influence 
prescribing practice can be asked in a definitive manner. 
Because either an affirmative or a negative answer would 
be useful, the question must be asked. We do hope the 
use  of  individual  genetic  information  can  help  guide 
intelligent medication choices in the future: public and 
private funding bodies should support clinical trials with 
large  sample  sizes  in  an  effort  to  show  improved 
outcomes and cost effectiveness before this promise can 
be delivered to clinical practice.
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